vs
北方信托（CZNC）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
北方信托的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.0倍（$36.9M vs $35.5M），北方信托净利率更高（12.1% vs -304.2%，领先316.4%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 31.6%），北方信托自由现金流更多（$30.1M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 19.7%）
北方信托是一家总部位于美国伊利诺伊州芝加哥市的金融服务企业，主要服务对象为企业、机构投资者与超高净值个人。它是美国规模领先的银行机构之一，也是美国持续经营历史最悠久的银行之一，截至2025年底，其管理资产规模达1.8万亿美元，托管资产规模达14.9万亿美元。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
CZNC vs RXRX — 直观对比
营收规模更大
CZNC
是对方的1.0倍
$35.5M
营收增速更快
RXRX
高出650.2%
31.6%
净利率更高
CZNC
高出316.4%
-304.2%
自由现金流更多
CZNC
多$77.4M
$-47.3M
两年增速更快
RXRX
近两年复合增速
19.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $36.9M | $35.5M |
| 净利润 | $4.5M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 14.6% | -304.8% |
| 净利率 | 12.1% | -304.2% |
| 营收同比 | 31.6% | 681.7% |
| 净利润同比 | -45.4% | 39.6% |
| 每股收益（稀释后） | — | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CZNCRXRX
| Q4 25 | $36.9M | $35.5M | ||
| Q3 25 | $29.6M | $5.2M | ||
| Q2 25 | $29.3M | $19.2M | ||
| Q1 25 | $27.0M | $14.7M | ||
| Q4 24 | $28.0M | $4.5M | ||
| Q3 24 | $27.3M | $26.1M | ||
| Q2 24 | $27.3M | $14.4M | ||
| Q1 24 | $25.7M | $13.8M |
净利润CZNCRXRX
| Q4 25 | $4.5M | $-108.1M | ||
| Q3 25 | $6.6M | $-162.3M | ||
| Q2 25 | $6.1M | $-171.9M | ||
| Q1 25 | $6.3M | $-202.5M | ||
| Q4 24 | $8.2M | $-178.9M | ||
| Q3 24 | $6.4M | $-95.8M | ||
| Q2 24 | $6.1M | $-97.5M | ||
| Q1 24 | $5.3M | $-91.4M |
毛利率CZNCRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率CZNCRXRX
| Q4 25 | 14.6% | -304.8% | ||
| Q3 25 | 27.1% | -3327.6% | ||
| Q2 25 | 25.7% | -916.8% | ||
| Q1 25 | 28.6% | -1297.9% | ||
| Q4 24 | 36.1% | -4042.4% | ||
| Q3 24 | 28.6% | -377.1% | ||
| Q2 24 | 27.4% | -697.4% | ||
| Q1 24 | 25.1% | -698.4% |
净利率CZNCRXRX
| Q4 25 | 12.1% | -304.2% | ||
| Q3 25 | 22.2% | -3135.3% | ||
| Q2 25 | 20.9% | -894.2% | ||
| Q1 25 | 23.3% | -1373.3% | ||
| Q4 24 | 29.2% | -3935.5% | ||
| Q3 24 | 23.3% | -367.5% | ||
| Q2 24 | 22.4% | -676.6% | ||
| Q1 24 | 20.6% | -662.4% |
每股收益（稀释后）CZNCRXRX
| Q4 25 | — | $-0.17 | ||
| Q3 25 | $0.42 | $-0.36 | ||
| Q2 25 | $0.40 | $-0.41 | ||
| Q1 25 | $0.41 | $-0.50 | ||
| Q4 24 | $0.53 | $-0.56 | ||
| Q3 24 | $0.41 | $-0.34 | ||
| Q2 24 | $0.40 | $-0.40 | ||
| Q1 24 | $0.35 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $46.1M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $341.7M | $1.1B |
| 总资产 | $3.1B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资CZNCRXRX
| Q4 25 | $46.1M | $743.3M | ||
| Q3 25 | $123.1M | $659.8M | ||
| Q2 25 | $99.6M | $525.1M | ||
| Q1 25 | $114.7M | $500.5M | ||
| Q4 24 | $126.2M | $594.4M | ||
| Q3 24 | $184.2M | $427.6M | ||
| Q2 24 | $100.4M | $474.3M | ||
| Q1 24 | $46.4M | $296.3M |
总债务CZNCRXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益CZNCRXRX
| Q4 25 | $341.7M | $1.1B | ||
| Q3 25 | $294.0M | $1.0B | ||
| Q2 25 | $286.4M | $919.1M | ||
| Q1 25 | $281.8M | $933.9M | ||
| Q4 24 | $275.3M | $1.0B | ||
| Q3 24 | $277.3M | $524.6M | ||
| Q2 24 | $263.2M | $584.4M | ||
| Q1 24 | $261.7M | $401.2M |
总资产CZNCRXRX
| Q4 25 | $3.1B | $1.5B | ||
| Q3 25 | $2.7B | $1.4B | ||
| Q2 25 | $2.6B | $1.3B | ||
| Q1 25 | $2.6B | $1.3B | ||
| Q4 24 | $2.6B | $1.4B | ||
| Q3 24 | $2.7B | $726.5M | ||
| Q2 24 | $2.6B | $775.9M | ||
| Q1 24 | $2.5B | $557.8M |
负债/权益比CZNCRXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.0M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $30.1M | $-47.3M |
| 自由现金流率自由现金流/营收 | 81.6% | -133.1% |
| 资本支出强度资本支出/营收 | 5.2% | 3.5% |
| 现金转化率经营现金流/净利润 | 7.17× | — |
| 过去12个月自由现金流最近4个季度 | $50.1M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流CZNCRXRX
| Q4 25 | $32.0M | $-46.1M | ||
| Q3 25 | $11.3M | $-117.4M | ||
| Q2 25 | $8.5M | $-76.4M | ||
| Q1 25 | $1.6M | $-132.0M | ||
| Q4 24 | $33.0M | $-115.4M | ||
| Q3 24 | $6.6M | $-59.2M | ||
| Q2 24 | $8.6M | $-82.2M | ||
| Q1 24 | $5.7M | $-102.3M |
自由现金流CZNCRXRX
| Q4 25 | $30.1M | $-47.3M | ||
| Q3 25 | $10.9M | $-117.6M | ||
| Q2 25 | $8.0M | $-79.6M | ||
| Q1 25 | $1.0M | $-133.8M | ||
| Q4 24 | $31.1M | $-116.7M | ||
| Q3 24 | $6.4M | $-63.8M | ||
| Q2 24 | $8.0M | $-83.4M | ||
| Q1 24 | $5.0M | $-109.0M |
自由现金流率CZNCRXRX
| Q4 25 | 81.6% | -133.1% | ||
| Q3 25 | 36.9% | -2272.5% | ||
| Q2 25 | 27.4% | -413.9% | ||
| Q1 25 | 3.9% | -907.4% | ||
| Q4 24 | 111.1% | -2567.7% | ||
| Q3 24 | 23.6% | -244.6% | ||
| Q2 24 | 29.2% | -578.5% | ||
| Q1 24 | 19.4% | -789.9% |
资本支出强度CZNCRXRX
| Q4 25 | 5.2% | 3.5% | ||
| Q3 25 | 1.4% | 4.7% | ||
| Q2 25 | 1.7% | 16.4% | ||
| Q1 25 | 2.0% | 12.4% | ||
| Q4 24 | 6.8% | 28.6% | ||
| Q3 24 | 0.5% | 17.5% | ||
| Q2 24 | 2.4% | 8.2% | ||
| Q1 24 | 2.9% | 48.2% |
现金转化率CZNCRXRX
| Q4 25 | 7.17× | — | ||
| Q3 25 | 1.73× | — | ||
| Q2 25 | 1.39× | — | ||
| Q1 25 | 0.25× | — | ||
| Q4 24 | 4.04× | — | ||
| Q3 24 | 1.04× | — | ||
| Q2 24 | 1.41× | — | ||
| Q1 24 | 1.08× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
